Our Pipeline

Our integrated approach is uniquely positioned to disrupt solid tumor therapeutics. Our initial areas of development will focus on the parallel advancement of Umoja’s core platforms with the goal of bringing together these technologies as a scalable, next-generation process for solid tumor immunotherapy.


Our lead candidate programs are:

VivoVec UB-VV100 engineering cells with RACR-CD19 CAR

For hematological cancers

TumorTag UB-TT170 with Ex Vivo TagCAR T cells

In pediatric osteosarcoma

Umoja has an active IND in effect with the FDA to investigate the application of our TumorTag technology in pediatric osteosarcoma. We are planning to begin a phase 1 clinical trial in late 2021.

Concurrently, we are working to establish our lead candidate for our VivoVec platform and will pursue further development throughout 2021 with plans for IND submission in the second half of 2022.

Umoja is driven by a bold and unified vision to transform cancer treatment and improve quality of life. We are a diverse group of drug development experts, scientists and researchers that are skilled, passionate, persistent, and committed to finding a way to break through the current challenges seen in immuno-oncology today.